{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T18:17:07Z","timestamp":1775499427000,"version":"3.50.1"},"reference-count":40,"publisher":"Deutscher Arzte-Verlag GmbH","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.3238\/arztebl.m2021.0157","type":"journal-article","created":{"date-parts":[[2021,7,27]],"date-time":"2021-07-27T14:55:24Z","timestamp":1627397724000},"source":"Crossref","is-referenced-by-count":6,"title":["Antithrombotic Treatment for Peripheral Arterial Occlusive Disease"],"prefix":"10.3238","author":[{"given":"David","family":"Hardung","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Behne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehmet","family":"Boral","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carsten","family":"Giesche","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralf","family":"Langhoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"11437","published-online":{"date-parts":[[2021,8,9]]},"reference":[{"key":"10.3238\/arztebl.m2021.0157_ref1","doi-asserted-by":"crossref","unstructured":"Malyar N, F\u00fcrstenberg T, Wellmann J, et al.: Recent trends in morbidity and in-hospital outcomes of in-patients with peripheral arterial disease: a nationwide population-based analysis. Eur Heart J 2013; 34: 2706\u201314","DOI":"10.1093\/eurheartj\/eht288"},{"key":"10.3238\/arztebl.m2021.0157_ref2","doi-asserted-by":"crossref","unstructured":"Agnelli G, Belch JJF, Baumgartner I, Giovas P, Hoffmann U: Morbidity and mortality associated with atherosclerotic peripheral artery disease: a systematic review. Atherosclerosis 2020; 293: 94\u2013100","DOI":"10.1016\/j.atherosclerosis.2019.09.012"},{"key":"10.3238\/arztebl.m2021.0157_ref3","doi-asserted-by":"crossref","unstructured":"Fortington LV, Rommers GM, Geertzen JH, Postema K, Dijkstra PU: Mobility in elderly people with a lower limb amputation: a systematic review. J Am Med Dir Assoc 2012; 13: 319\u201325","DOI":"10.1016\/j.jamda.2010.12.097"},{"key":"10.3238\/arztebl.m2021.0157_ref4","doi-asserted-by":"crossref","unstructured":"Stern JR, Wong CK, Yerovinkina M, et al.: A meta-analysis of long-term mortality and associated risk factors following lower extremity amputation. Ann Vasc Surg 2017; 42: 322\u20137","DOI":"10.1016\/j.avsg.2016.12.015"},{"key":"10.3238\/arztebl.m2021.0157_ref5","doi-asserted-by":"crossref","unstructured":"Bonaca MP, Gutierrez JA, Creager MA, et al.: Acute limb ischemia and outcomes with vorapaxar in patients with peripheral artery disease: results from the trial to assess the effects of vorapaxar in preventing heart attack and stroke in patients with atherosclerosis-thrombolysis in myocardial infarction 50 (TRA2\u00b0P-TIMI 50). Circulation 2016; 133: 997\u20131005","DOI":"10.1161\/CIRCULATIONAHA.115.019355"},{"key":"10.3238\/arztebl.m2021.0157_ref6","doi-asserted-by":"crossref","unstructured":"Valentijn TM, Stolker RJ: Lessons from the REACH Registry in Europe. Curr Vasc Pharmacol 2012; 10: 725\u20137","DOI":"10.2174\/157016112803520774"},{"key":"10.3238\/arztebl.m2021.0157_ref7","doi-asserted-by":"crossref","unstructured":"Berger JS, Abramson BL, Lopes RD, et al.: Ticagrelor versus clopidogrel in patients with symptomatic peripheral artery disease and prior coronary artery disease: insights from the EUCLID trial. Vasc Med 2018; 23: 523\u201330","DOI":"10.1177\/1358863X18775594"},{"key":"10.3238\/arztebl.m2021.0157_ref8","doi-asserted-by":"crossref","unstructured":"Bonaca MP, Bhatt DL, Storey RF, et al.: Ticagrelor for prevention of ischemic events after myocardial infarction in patients with peripheral artery disease. J Am Coll Cardiol 2016; 67: 2719\u201328 CrossRef","DOI":"10.1016\/j.jacc.2016.03.524"},{"key":"10.3238\/arztebl.m2021.0157_ref9","doi-asserted-by":"crossref","unstructured":"Savarese G, Reiner MF, Uijl A, et al.: Antithrombotic therapy and major adverse limb events in patients with chronic lower extremity arterial disease: systematic review and meta-analysis from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy in Collaboration with the European Society of Cardiology Working Group on Aorta and Peripheral Vascular Diseases. Eur Heart J Cardiovasc Pharmacother 2020; 6: 86\u201393 CrossRef","DOI":"10.1093\/ehjcvp\/pvz036"},{"key":"10.3238\/arztebl.m2021.0157_ref10","doi-asserted-by":"crossref","unstructured":"Aboyans V, Ricco JB, Bartelink MEL, et al.: 2017 ESC guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the European Society for Vascular Surgery (ESVS). Eur J Vasc Endovasc Surg 2018; 55: 305\u201368","DOI":"10.1016\/j.ejvs.2018.03.004"},{"key":"10.3238\/arztebl.m2021.0157_ref11","doi-asserted-by":"crossref","unstructured":"Frank U, Nikol S, Belch J, et al.: ESVM guideline on peripheral arterial disease. Vasa 2019; 48: 1\u201379","DOI":"10.1024\/0301-1526\/a000834"},{"key":"10.3238\/arztebl.m2021.0157_ref12","unstructured":"AWMF: S3-Leitlinie zur Diagnostik, Therapie und Nachsorge der peripheren arteriellen Verschlusskrankheit. AWMF-Register Nr. 065\/003 Entwicklungsstufe 3. Stand: 30.11.2015 (in \u00dcberarbeitung); https:\/\/www.awmf.org\/leitlinien\/detail\/ll\/065-003.html (last accessed on 9 May 2021)."},{"key":"10.3238\/arztebl.m2021.0157_ref13","unstructured":"NICE: Clinical guideline [CG147] Peripheral arterial disease: diagnosis and management. 2012, updated 2020. www.nice.org.uk\/guidance\/cg147 (last accessed on 25 April 2021)."},{"key":"10.3238\/arztebl.m2021.0157_ref14","unstructured":"NICE: Technology appraisal guidance [TA607] Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery disease. 2019. www.nice.org.uk\/Guidance\/TA607 (last accessed on 25 April 2021)."},{"key":"10.3238\/arztebl.m2021.0157_ref15","doi-asserted-by":"crossref","unstructured":"Hess CN, Norgren L, Ansel GM, et al.: A structured review of antithrombotic therapy in peripheral artery disease with a focus on revascularization: a TASC (InterSociety Consensus for the Management of Peripheral Artery Disease) Initiative. Circulation 2017; 135: 2534\u201355","DOI":"10.1161\/CIRCULATIONAHA.117.024469"},{"key":"10.3238\/arztebl.m2021.0157_ref16","doi-asserted-by":"crossref","unstructured":"Ambler GK, Waldron CA, Contractor UB, Hinchliffe RJ, Twine CP: Umbrella review and meta-analysis of antiplatelet therapy for peripheral artery disease. Br J Surg 2020; 107: 20\u201332","DOI":"10.1002\/bjs.11384"},{"key":"10.3238\/arztebl.m2021.0157_ref17","doi-asserted-by":"crossref","unstructured":"De Carlo M, Di Minno G, Sayre T, Fazeli MS, Siliman G, Cimminiello C: Efficacy and safety of antiplatelet therapies in aymptomatic peripheral artery disease: a systematic review and network meta-analysis. Curr Vasc Pharmacol 2021; 19: 1\u201314","DOI":"10.2174\/1570161118666200820141131"},{"key":"10.3238\/arztebl.m2021.0157_ref18","doi-asserted-by":"crossref","unstructured":"Hiatt WR, Fowkes FG, Heizer G, et al.: Ticagrelor versus clopidogrel in symptomatic peripheral artery disease. N Engl J Med 2017; 376: 32\u201340","DOI":"10.1056\/NEJMoa1611688"},{"key":"10.3238\/arztebl.m2021.0157_ref19","doi-asserted-by":"crossref","unstructured":"Anand SS, Bosch J, Eikelboom JW, et al.: Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet 2018; 391: 219\u201329","DOI":"10.1016\/S0140-6736(17)32409-1"},{"key":"10.3238\/arztebl.m2021.0157_ref20","doi-asserted-by":"crossref","unstructured":"Anand SS, Caron F, Eikelboom JW, et al.: Major adverse limb events and mortality in patients with peripheral artery disease: The COMPASS Trial. J Am Coll Cardiol 2018; 71: 2306\u201315","DOI":"10.1016\/j.jacc.2018.03.008"},{"key":"10.3238\/arztebl.m2021.0157_ref21","doi-asserted-by":"crossref","unstructured":"Hinchliffe RJ, Forsythe RO, Apelqvist J, et al.: Guidelines on diagnosis, prognosis, and management of peripheral artery disease in patients with foot ulcers and diabetes (IWGDF 2019 update). Diabetes Metab Res Rev 2020; 36: e3276","DOI":"10.1002\/dmrr.3276"},{"key":"10.3238\/arztebl.m2021.0157_ref22","doi-asserted-by":"crossref","unstructured":"Stalling P, Engelbertz C, L\u00fcders F, et al.: Unmet medical needs in intermittent Claudication with diabetes and coronary artery disease\u2014a \u201ereal-world\u201c analysis on 21197 PAD patients. Clin Cardiol 2019; 42: 629\u201336","DOI":"10.1002\/clc.23186"},{"key":"10.3238\/arztebl.m2021.0157_ref23","doi-asserted-by":"crossref","unstructured":"Balletshofer B, Ito W, Lawall H, et al.: Position paper on the diagnosis and treatment of peripheral arterial disease (PAD) in people with diabetes mellitus. Exp Clin Endocrinol Diabetes 2019; 127: S105\u2013S3","DOI":"10.1055\/a-1018-9250"},{"key":"10.3238\/arztebl.m2021.0157_ref24","doi-asserted-by":"crossref","unstructured":"Cosentino F, Grant PJ, Aboyans V, et al.: ESC Scientific Document Group. 2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J 2020; 41: 255\u2013323","DOI":"10.1093\/eurheartj\/ehz486"},{"key":"10.3238\/arztebl.m2021.0157_ref25","doi-asserted-by":"crossref","unstructured":"Bhatt DL, Eikelboom JW, Connolly SJ, et al.: Role of combination antiplatelet and anticoagulation therapy in diabetes mellitus and cardiovascular disease: insights from the COMPASS trial. Circulation 2020; 141: 1841\u201354","DOI":"10.1161\/CIRCULATIONAHA.120.046448"},{"key":"10.3238\/arztebl.m2021.0157_ref26","doi-asserted-by":"crossref","unstructured":"Lamberts M, Gislason GH, Lip GY, et al.: Antiplatelet therapy for stable coronary artery disease in atrial fibrillation patients taking an oral anticoagulant: a nationwide cohort study. Circulation 2014; 129: 1577\u201385","DOI":"10.1161\/CIRCULATIONAHA.113.004834"},{"key":"10.3238\/arztebl.m2021.0157_ref27","doi-asserted-by":"crossref","unstructured":"Zhang H, Xue Z, Yi D, Li X, Tan Y, Li J: Non-vitamin K antagonist oral anticoagulants versus warfarin in patients with atrial fibrillation with coronary or peripheral artery disease. Int Heart J 2020; 61: 231\u20138","DOI":"10.1536\/ihj.19-202"},{"key":"10.3238\/arztebl.m2021.0157_ref28","doi-asserted-by":"crossref","unstructured":"Hussain MA, Al-Omran M, Creager MA, Anand SS, Verma S, Bhatt DL: Antithrombotic therapy for peripheral artery disease: recent advances. J Am Coll Cardiol 2018; 71: 2450\u201367","DOI":"10.1016\/j.jacc.2018.03.483"},{"key":"10.3238\/arztebl.m2021.0157_ref29","doi-asserted-by":"crossref","unstructured":"Steg PG, Bhatt DL: Is there really a benefit to net clinical benefit in testing antithrombotics? Circulation 2018; 137: 1429\u201331","DOI":"10.1161\/CIRCULATIONAHA.117.033442"},{"key":"10.3238\/arztebl.m2021.0157_ref30","doi-asserted-by":"crossref","unstructured":"Tsai HH, Kim JS, Jouvent E, Gurol ME: Updates on prevention of kemorrhagic and lacunar strokes. J Stroke 2018; 20: 167\u201379","DOI":"10.5853\/jos.2018.00787"},{"key":"10.3238\/arztebl.m2021.0157_ref31","doi-asserted-by":"crossref","unstructured":"Kollias AN, Ulbig MW: Diabetic retinopathy: early diagnosis and effective treatment. Dtsch Arztebl Int 2010; 107: 75\u201383","DOI":"10.3238\/arztebl.2010.0075"},{"key":"10.3238\/arztebl.m2021.0157_ref32","doi-asserted-by":"crossref","unstructured":"Qureshi MI, Li HL, Ambler GK, et al.: Antiplatelet and anticoagulant use in randomised trials of patients undergoing endovascular intervention for peripheral arterial disease: systematic review and narrative synthesis. Eur J Vasc Endovasc Surg 2020; 60: 77\u201387 CrossRef","DOI":"10.1016\/j.ejvs.2020.03.010"},{"key":"10.3238\/arztebl.m2021.0157_ref33","doi-asserted-by":"crossref","unstructured":"Darmon A, Bhatt DL, Elbez Y, et al.: External applicability of the COMPASS trial: an analysis of the reduction of atherothrombosis for continued health (REACH) registry. Eur Heart J 2018; 39: 750\u2013\u20137a","DOI":"10.1093\/eurheartj\/ehx658"},{"key":"10.3238\/arztebl.m2021.0157_ref34","unstructured":"Bayer Vital GmbH: Sicherheitshinweise zur Anwendung von Xarelto (Rivaroxaban) f\u00fcr den behandelnden Arzt. Version 6. Freigabe durch das Bundesinstitut f\u00fcr Arzneimittel und Medizinprodukte (BfArM): 03\/2020."},{"key":"10.3238\/arztebl.m2021.0157_ref35","doi-asserted-by":"crossref","unstructured":"Beiswenger AC, Jo A, Harth K, Kumins NH, Shishehbor MH, Kashyap VS: A systematic review of the efficacy of aspirin monotherapy versus other antiplatelet therapy regimens in peripheral arterial disease. J Vasc Surg 2018; 67: 1922\u201332","DOI":"10.1016\/j.jvs.2018.02.047"},{"key":"10.3238\/arztebl.m2021.0157_ref36","doi-asserted-by":"crossref","unstructured":"Bonaca MP, Bauersachs RM, Anand SS, et al.: Rivaroxaban in peripheral artery disease after revascularization. N Engl J Med 2020; 382: 1994\u20132004","DOI":"10.1056\/NEJMoa2000052"},{"key":"10.3238\/arztebl.m2021.0157_ref37","doi-asserted-by":"crossref","unstructured":"Hiatt WR, Bonaca MP, Patel MR, et al.: Rivaroxaban and aspirin in peripheral artery disease lower extremity revascularization: impact of concomitant clopidogrel on efficacy and safety. Circulation 2020; 142: 2219\u201330","DOI":"10.1161\/CIRCULATIONAHA.120.050465"},{"key":"10.3238\/arztebl.m2021.0157_ref38","doi-asserted-by":"crossref","unstructured":"Belch JJ, Dormandy J, CASPAR Writing Committee, et al.: Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial. J Vasc Surg 2010; 52: 825\u201333","DOI":"10.1016\/j.jvs.2010.04.027"},{"key":"10.3238\/arztebl.m2021.0157_ref39","doi-asserted-by":"crossref","unstructured":"Bedenis R, Lethaby A, Maxwell H, Acosta S, Prins MH: Antiplatelet agents for preventing thrombosis after peripheral arterial bypass surgery. Cochrane Database Syst Rev 2015; 2015: CD000535","DOI":"10.1002\/14651858.CD000535.pub3"},{"key":"10.3238\/arztebl.m2021.0157_ref40","doi-asserted-by":"crossref","unstructured":"Obi AT, Thompson JR, Beaulieu RJ, et al.: Bleeding and thrombotic outcomes associated with postoperative use of direct oral anticoagulants after open peripheral artery bypass procedures. J Vasc Surg 2020; 72: 1996\u20132005","DOI":"10.1016\/j.jvs.2020.02.021"}],"container-title":["Deutsches \u00c4rzteblatt international"],"original-title":[],"link":[{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.m2021.0157","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,6]],"date-time":"2021-12-06T10:00:00Z","timestamp":1638784800000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.m2021.0157"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,9]]},"references-count":40,"URL":"https:\/\/doi.org\/10.3238\/arztebl.m2021.0157","relation":{},"ISSN":["1866-0452"],"issn-type":[{"value":"1866-0452","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,9]]}}}